Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor
- PMID: 22585684
- DOI: 10.1002/eji.201142179
Melanoma cells become resistant to NK-cell-mediated killing when exposed to NK-cell numbers compatible with NK-cell infiltration in the tumor
Abstract
During the past few years, a number of studies reported that different melanoma cell lines could be extensively lysed in vitro by IL-2-activated NK cells at appropriate effector/target ratios. Here, we show, by histological evaluation of different melanoma lesions, that NK/target-cell ratios compatible with those allowing efficient melanoma cell killing in vitro are hardly reached at the tumor site. We then investigated the outcome of cocultures established at low NK/melanoma cell ratios. After initial NK-mediated lysis, residual melanoma cells acquired resistance to IL-2-activated NK cells. This reflected primarily an increased expression, on melanoma cells, of classical and nonclassical HLA class I molecules, accompanied by a partial downregulation of NKG2D-ligands, and was dependent on NK-mediated IFN-γ release. Consistently, melanoma lesions showed a higher HLA class I expression on tumor cells that were proximal to infiltrating NK cells. In long-term cocultures, the "protective phenotype" acquired by melanoma cells was lost over time. However, this phenomenon was counteracted by downregulation of relevant activating receptors in cocultured NK cells. Analysis of different NK-cell-activating cytokines indicated that IL-15 can partially overcome this novel tumor escape mechanism suggesting that IL-15, rather than IL-2, may be eligible for NK-cell-based immunotherapy.
© 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.
Similar articles
-
Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.J Biol Response Mod. 1990 Apr;9(2):113-26. J Biol Response Mod. 1990. PMID: 2111373
-
Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation.Cytokine. 2008 Apr;42(1):128-36. doi: 10.1016/j.cyto.2008.01.003. Epub 2008 Feb 15. Cytokine. 2008. PMID: 18280748
-
NK cells from malignant pleural effusions are not anergic but produce cytokines and display strong antitumor activity on short-term IL-2 activation.Eur J Immunol. 2013 Feb;43(2):550-61. doi: 10.1002/eji.201242783. Epub 2013 Jan 15. Eur J Immunol. 2013. PMID: 23192659
-
Dual effects of cytokines in regulation of MHC-unrestricted cell mediated cytotoxicity.Crit Rev Immunol. 1993;13(1):1-34. Crit Rev Immunol. 1993. PMID: 8466640 Review.
-
NK cell recognition and killing of melanoma cells is controlled by multiple activating receptor-ligand interactions.J Innate Immun. 2011;3(4):365-73. doi: 10.1159/000328505. Epub 2011 May 11. J Innate Immun. 2011. PMID: 21576932 Review.
Cited by
-
NK Cell-Based Immunotherapy in Cancer Metastasis.Cancers (Basel). 2018 Dec 28;11(1):29. doi: 10.3390/cancers11010029. Cancers (Basel). 2018. PMID: 30597841 Free PMC article. Review.
-
Human NK cells: surface receptors, inhibitory checkpoints, and translational applications.Cell Mol Immunol. 2019 May;16(5):430-441. doi: 10.1038/s41423-019-0206-4. Epub 2019 Feb 18. Cell Mol Immunol. 2019. PMID: 30778167 Free PMC article. Review.
-
Modulation of NK cells with checkpoint inhibitors in the context of cancer immunotherapy.Cancer Immunol Immunother. 2019 May;68(5):861-870. doi: 10.1007/s00262-019-02336-6. Epub 2019 Apr 5. Cancer Immunol Immunother. 2019. PMID: 30953117 Free PMC article. Review.
-
A multi-organ-on-chip to recapitulate the infiltration and the cytotoxic activity of circulating NK cells in 3D matrix-based tumor model.Front Bioeng Biotechnol. 2022 Jul 25;10:945149. doi: 10.3389/fbioe.2022.945149. eCollection 2022. Front Bioeng Biotechnol. 2022. PMID: 35957642 Free PMC article.
-
Targeting natural killer cells in solid tumors.Cell Mol Immunol. 2019 May;16(5):415-422. doi: 10.1038/s41423-019-0224-2. Epub 2019 Mar 25. Cell Mol Immunol. 2019. PMID: 30911118 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous